On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
FridaySep 25, 2020 2:41 pm

QualityStocksNewsBreaks – 180 Life Sciences Corp. Advancing Lead Program, Plans Additional Clinical Trials

180 Life Sciences, a clinical-stage biotechnology company, is dedicated to producing solutions designed to battle inflammation when the body’s natural processes go awry. The company’s primary focus is to treat fibrosis and inflammation using anti-TNF therapy, designed to block the activity of TNF, a substance in the body that can cause inflammation and lead to immune-system diseases. The company is advancing on this front as discussed by a recent article that reads, “180 Life Sciences’ lead program is in phase 2b/3 clinical trials and expects to deliver its first results next year. Other clinical trials planned by the company are…

Continue Reading

FridaySep 25, 2020 2:18 pm

QualityStocksNewsBreaks – SRAX Inc.’s (NASDAQ: SRAX) Sequire Provides Key Insight for Public Company Execs

SRAX (NASDAQ: SRAX), a provider of digital-marketing and consumer data-management technology products, gives public companies an edge with critical data to successfully activate media campaigns, engage shareholders and attract investment. The company’s data analytics platform – Sequire – has proven a key tool for decision makers in the public realm, recently doubling its user base to amass over 1 million active investors and traders. A recent article discussing this quotes SRAX founder and CEO Christopher Miglino, who states, “We are creating a community of public company executives that are taking back their data. For too long these leaders have relied…

Continue Reading

FridaySep 25, 2020 2:07 pm

QualityStocksNewsBreaks – Cybin Corp. Leverages Two-Pronged Approach to Target Psychedelic, Nutraceutical Sectors

Cybin Corp., a Canada-based life-science company, looks to benefit from its growing footprint in two billion-dollar markets: nutraceuticals and psychedelic drugs. Both sectors are projected to see significant growth in the coming years. The global nutraceutical market was valued at $382.51 billion in 2019 and is expected to grow at an 8.3% compound annual growth rate (“CAGR”) over the next seven years. Meanwhile, the psychedelic drugs market is projected to reach $6.85 billion by 2027. Cybin’s business model is structured around two wholly owned divisions focused on targeting both promising spaces. A recent article discussing this reads, “Cybin is committed…

Continue Reading

FridaySep 25, 2020 1:48 pm

QualityStocksNewsBreaks – Trxade Group Inc. (NASDAQ: MEDS) Shines Spotlight on Dynamic Platform Capabilities

Trxade Group (NASDAQ: MEDS), an integrated drug-procurement, delivery and health-care platform, recently had the opportunity to showcase its growing medical technology accomplishments at multiple virtual investor conferences. Trxade Group CEO Suren Ajjarapu took the company’s message well beyond physical borders to virtual summits in the month of September, providing insight into the dynamic capabilities and expansion of the Trxade Exchange platform. A recent article discussing this reads, “Trxade Group has been building its B2B platform into a B2C-friendly portfolio that helps independent local pharmacies compete with large-scale retail chains through drug pricing transparency and network strength. The platform also assists health…

Continue Reading

ThursdaySep 24, 2020 3:50 pm

QualityStocksNewsBreaks – Pure Extract Technologies Inc. Eyes Functional Mushroom Sector for Initial Product Lines

Pure Extract Technologies, a private, plant-based extraction company poised to enter the commercial cannabis sector with a new vertical in functional mushrooms, has seized the opportunity to reveal its business development strategy (https://ibn.fm/6OXiR). A recent article discussing this reads, “As Pure Extracts positions itself to become the premier commercialization and manufacturing partner for functional companies going forward, the company plans to center its initial product lines on functional mushroom products. In its bid to do so, the company is applying for a Natural Health Products site license with Health Canada, which, once received, will enable Pure Extracts to begin producing clinical…

Continue Reading

ThursdaySep 24, 2020 3:26 pm

QualityStocksNewsBreaks – Why Kaival Brands Innovations Group Inc. (KAVL) Is ‘One to Watch’

Kaival Brands (OTCQB: KAVL), a company focused on developing products into mature, dominant brands, recently entered into a partnership with Bidi Vapor LLC. Under the partnership, Kaival Brands has exclusive global distribution rights for the Bidi(TM) Stick, an innovative product made from high-quality components and equipped with a long-lasting battery and class A nicotine. The move has already had a positive impact on Kaival Brands, assisting the company with expedited growth. A recent article discussing the company reads, “Kaival Brands is dedicated to developing innovative and viable options for adults who use tobacco and vape products and want a premium…

Continue Reading

WednesdaySep 23, 2020 3:56 pm

QualityStocksNewsBreaks – The Movie Studio Inc. (MVES) Poised in VOD as ‘Cord Cutters’ Ditch Cable, Keep the Screen

The Movie Studios (OTC: MVES), an independent motion-picture production and distribution company, is poised to benefit in the growing video on demand (“VOD”) space. A recent Protocol publication indicates that, while cable and TV subscribers are down, a growing number of cord cutters haven’t stopped watching the screen and are moving to VOD (https://ibn.fm/Qp07N). A recent article addressing this trend discusses The Movie Studio’s positioning and strategy as it works to establish a proprietary over the top (“OTT”) VOD platform to deliver to today’s consumers. The piece reads, “Netflix and Disney+ are big players in the VOD space, but a growing…

Continue Reading

WednesdaySep 23, 2020 3:34 pm

QualityStocksNewsBreaks – InsuraGuest Technologies Inc. (TSX.V: ISGI) (OTC: IGSTF) Looks Beyond Hotels to Deliver Insurtech Solutions

InsuraGuest Technologies (TSX.V: ISGI) (OTC: IGSTF), an innovative insurtech leader, continues to disrupt the insurance landscape by delivering digital insurance to multiple sectors through its proprietary software platform. The company initially targeted the hospitality market, providing specialized coverages to member hotels and vacation rental properties, enabling them to benefit from an additional layer of protection that prevents the need to make GL claims if an InsuraGuest-covered claim occurs. With an aim to transform the way insurance is delivered, the company has further expanded its reach through strategic partnerships and moves, and InsuraGuest is positioned to deliver to multiple other sectors.…

Continue Reading

WednesdaySep 23, 2020 3:12 pm

QualityStocksNewsBreaks – Sharing Services Global Corporation’s (SHRG) Philosophy Distances from Cutthroats, Follows Blue Ocean Strategy

Sharing Services Global (OTCQB: SHRG), a diversified holding company, is not only well positioned within the direct-selling industry, but distinct and operating out of its top tier. In its latest report, “2019 Direct Selling Business Results,” the World Federation of Direct Selling Associations announced that worldwide retail sales showed a year-over-year sales increase of 1.4% compared to 2018 while growing at a healthy pace in the long term (https://ibn.fm/sGx6p). The report also indicates that wellness — the product category where SHRG operates — continues to be the leader in the U.S. direct-selling landscape with 36% of total sales. The report…

Continue Reading

TuesdaySep 22, 2020 4:59 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP), Sub-Licensee Partner Advancing Lead Drug Candidate in First-Ever Phase 1 and Phase 2 Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing its leading drug candidate, Berubicin, to move forward with clinical trials in Poland. This move comes after sub-licensee WPD Pharmaceuticals Inc. has identified a contract research organization — Worldwide Clinical Trials — to coordinate and supervise Phase 1 and Phase 2 trials in the European country (http://ibn.fm/iFYph). A recent article discussing this reads, “Berubicin is proposed for the treatment of glioblastoma multiforme (‘GBM’), an aggressive and incurable form of brain cancer. Berubicin also…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered